Innate Pharma (XPAR:IPH) Long-Term Capital Lease Obligation : €0.35 Mil (As of Dec. 2023)

View and export this data going back to 2006. Start your Free Trial

What is Innate Pharma Long-Term Capital Lease Obligation?

Innate Pharma's Long-Term Capital Lease Obligation for the quarter that ended in Dec. 2023 was €0.35 Mil.

Innate Pharma's quarterly Long-Term Capital Lease Obligation declined from Dec. 2022 (€1.22 Mil) to Jun. 2023 (€0.00 Mil) but then increased from Jun. 2023 (€0.00 Mil) to Dec. 2023 (€0.35 Mil).

Innate Pharma's annual Long-Term Capital Lease Obligation declined from Dec. 2021 (€2.01 Mil) to Dec. 2022 (€1.22 Mil) and declined from Dec. 2022 (€1.22 Mil) to Dec. 2023 (€0.35 Mil).

Innate Pharma Long-Term Capital Lease Obligation Historical Data

The historical data trend for Innate Pharma's Long-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Innate Pharma Long-Term Capital Lease Obligation Chart

Innate Pharma Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Long-Term Capital Lease Obligation

Get a 7-Day Free Trial

2.49

2.76

2.01

1.22

0.35

Innate Pharma Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Long-Term Capital Lease Obligation	Get a 7-Day Free Trial															2.01	-	1.22	-	0.35

Innate Pharma (XPAR:IPH) Long-Term Capital Lease Obligation Explanation

Long-Term Capital Lease Obligation are the amount due for long-term asset lease agreements that are nearly equivalent to asset purchases. Capital lease obligations are installment payments that constitute a payment of principal plus interest for the capital lease. The Short-Term Capital Lease Obligation is the portion of a Long-Term Capital Lease Obligation that is due over the next year.

Under US Generally Accepted Accounting Principles (GAAP), a capital lease is essentially equivalent to a purchase by the lessee if it meets the following criteria:

1. Ownership of the asset is transferred to the lessee at the end of the lease term;
2. The lease contains a bargain purchase option to buy the equipment at less than fair market value;
3. The lease term equals or exceeds 75% of the asset's estimated useful life;
4. The present value of the lease payments equals or exceeds 90% of the total original cost of the equipment.

Innate Pharma Long-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Innate Pharma's Long-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

Innate Pharma (XPAR:IPH) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Innate Pharma SA (XPAR:IPH) » Definitions » Long-Term Capital Lease Obligation

Comparable Companies

Traded in Other Exchanges

IPHYF:USA IPHA:USA 0EVI:UK IDDA:Germany

Address

117, Avenue de Luminy, Marseille, FRA, 13009

Website

https://www.innate-pharma.com

Innate Pharma SA is a clinical-stage biotechnology company. The company is engaged in discovering and developing first-in-class therapeutic antibodies that harness the innate immune system to improve cancer treatment and clinical outcomes for patients. It specializes in immuno-oncology, a new therapeutic field that is changing cancer treatment by mobilizing the power of the body's immune system to recognize and kill cancer cells. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, avdoralimab, and others.

Innate Pharma (XPAR:IPH) Headlines

No Headlines